Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.
Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH Jr, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ.
Choueiri TK, et al. Among authors: lee ch, lee cw.
ESMO Open. 2024 Dec 5;9(12):104073. doi: 10.1016/j.esmoop.2024.104073. Online ahead of print.
ESMO Open. 2024.
PMID: 39642635
Free article.